“3 Years of Tralokinumab Treatment Provides Long-Term Disease Control As Demonstrated by Clinically Meaningful Outcomes in Moderate-to-Severe Atopic Dermatitis”. 2022. SKIN The Journal of Cutaneous Medicine 6 (6): s78. https://doi.org/10.25251/skin.6.supp.78.